Real world outcomes using PD-1 antibodies and BRAF+MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
K SchumannC MauchK C KlespeC LoquaiU NikfarjamM SchlaakL AkcetinP KölblingerM HoellwerthM MeissnerG MengiA D BraunM MengoniReinhard DummerJ ManganaM A SindrilaruD RadmannC HafnerJ FreundK RappersbergerF WeihsengruberF MeissLydia ReinhardtF MeierB RainerE RichtigJulia Maria ResslerC HöllerT EigentlerTeresa AmaralW K PeitschU HillenW HarthF ZillerK SchattonT GambichlerL SusokL V MaulH LäubliD DebusC WeishauptS BörgerK SieversS HaferkampV ZenderowskiV A NguyenM WannerR GutzmerP TerheydenK KählerS EmmertAlexander ThiemM SachseS Gercken-RiedelK M KauneK M ThomsL HeinzerlingMarkus Vincent HepptS TratzmillerWolfram HoetzeneckerA ÖllingerA SteinerT PeinhauptM PoddaS SchmidUwe WollinaT BiedermannChristian PoschPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Despite recent advances in adjuvant melanoma treatment, early recurrence remains a significant clinical challenge. This study shows that total lymph node dissection does not reduce the risk of early melanoma recurrence and should only be considered in selected patients. Data further highlight that variables collected during clinical routine are unlikely to allow for a clinically relevant prediction of individual recurrence risk.
Keyphrases
- skin cancer
- end stage renal disease
- early stage
- free survival
- chronic kidney disease
- prostate cancer
- lymph node
- rectal cancer
- peritoneal dialysis
- prognostic factors
- electronic health record
- machine learning
- deep learning
- signaling pathway
- radical prostatectomy
- skeletal muscle
- neoadjuvant chemotherapy
- patient reported outcomes
- weight loss